Saleem Muhammad Rizwan, Khan Muhammad Talha
Dow Medical College Bachelor of Medicine, Bachelor of Surgery (MBBS), Dow University of Health Sciences, Karachi, Sindh, Pakistan.
Front Endocrinol (Lausanne). 2025 Apr 28;16:1533748. doi: 10.3389/fendo.2025.1533748. eCollection 2025.
Type 1 diabetes (T1D) arises from an autoimmune attack on pancreatic beta cells, leading to a reliance on external insulin to maintain glucose levels. In recent years, research has increasingly focused on preventive strategies for individuals at high risk. A promising new intervention in this field is Teplizumab, the first approved disease-modifying therapy for T1D. Teplizumab is designed to delay progression to stage 3 T1D in adults and children aged 8 years and older who are diagnosed with stage 2 T1D.
1型糖尿病（T1D）源于对胰腺β细胞的自身免疫攻击，导致依赖外源性胰岛素来维持血糖水平。近年来，研究越来越关注高危个体的预防策略。该领域一种有前景的新干预措施是替普珠单抗，它是首个被批准用于治疗1型糖尿病的疾病改善疗法。替普珠单抗旨在延缓8岁及以上被诊断为2期1型糖尿病的成人和儿童进展至3期1型糖尿病。
